UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 11, 2014
ROCK CREEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
|
Delaware
(State or other jurisdiction of incorporation) |
000-15324
(Commission File Number) |
52-1402131
(IRS Employer Identification No.) |
| |
|
|
| |
2040 Whitfield Avenue, Suite 300
Sarasota, Florida 34243
(Address of principal executive offices,
including zip code)
(804) 527-1970
(Registrant’s telephone number,
including area code) |
|
| |
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On December 11, 2014, Rock Creek Pharmaceuticals, Inc. (the
“Company”) issued the press release filed as Exhibit 99.1 to this Current Report on Form 8-K relating to a six-month
extension of the Company’s Nasdaq listing.
| |
Item 9.01. |
Financial Statements and Exhibits. |
| 99.1 | Press Release, dated December
11, 2014. |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
ROCK CREEK PHARMACEUTICALS, INC. |
| |
|
|
| |
|
|
| |
By: |
/s/ Michael J. Mullan |
| |
|
Michael J. Mullan |
| |
|
Chairman of the Board and Chief Executive Officer |
Date: December 11, 2014
Exhibit 99.1
Rock Creek Pharmaceuticals Announces Listing
Extension on NASDAQ
SARASOTA,
FL., December 11, 2014 – Rock Creek Pharmaceuticals, Inc.,
(NASDAQ: RCPI), a drug development
company focused on chronic inflammatory disease and neurologic disorders, announced today that it received notification from the
Nasdaq Stock Market, Inc. granting a six-month extension of its Nasdaq listing. The Company has until April 27, 2015 to maintain
a closing bid price of at least $1.00 for a minimum of 10 consecutive days to maintain compliance with Nasdaq listing requirements.
The extension is also subject to the condition that the Company provide certain written updates to Nasdaq during the extension
period and that Rock Creek file, on or before February 23, 2015, a preliminary proxy statement for a shareholder meeting for a
reverse stock split proposal.
In addition, the Company has applied to
transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market, which should go into effect on December 15, 2014.
The Company believes that The Nasdaq Capital Market is better suited to smaller companies, such as Rock Creek Pharmaceuticals.
About Anatabine Citrate:
Rock Creek Pharmaceutical's anatabine citrate is a small molecule,
cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. These anti-inflammatory effects have been
demonstrated through extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific
journal articles, covering models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. In addition, the company's
compilation of human exposure, safety and tolerability data, derived primarily from human clinical studies of the previously marketed
nutraceutical product, has provided important insights for clinical development.
About Rock Creek Pharmaceuticals, Inc.:
Rock Creek Pharmaceuticals, Inc. is an emerging drug development
company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies
for chronic inflammatory disease, neurologic disorders and behavioral health.
For more information, visit: http://www.rockcreekpharmaceuticals.com
Forward Looking Statements:
Certain statements contained in this
release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates,"
"estimates," "intends," "plans," "targets," "projects" and similar expressions.
The statements in this release are based upon the current beliefs and expectations of our company's management and are subject
to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous
factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies,
the challenges inherent in new product development initiatives, including the continued development and approval of anti-inflammatory
drug candidates, the effect of any competitive products, our ability to license and protect our intellectual property, our ability
to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation,
potential litigation by or against us, any governmental review of our products or practices and the outcome of the ongoing investigations
as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without
limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on March 17, 2014 and our latest 10-Q
Report filed onNovember 10, 2014. We undertake no duty to update any forward-looking statement or any information contained in
this press release or in other public disclosures at any time.
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals
2040 Whitfield Avenue, Suite 300
Sarasota, FL 34243
Direct: 941-251-0488
tjenkins@rockcreekpharmaceuticals.com
Stephanie Carrington
Investors
Integrated Corporate Relations, Inc. (ICR): Redefining Strategic
Communications
685 Third Avenue, 2nd Floor,
New York, NY 10017
(646) 277-1282
stephanie.carrington@icrinc.com
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024
